Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by sylvain_007on Feb 21, 2021 7:51am
405 Views
Post# 32620837

A small reflection on the current reality!

A small reflection on the current reality!
Although THRM remains at the forefront of the field, further news will be required to confirm the approval and then the awarding of contracts. Patience is required for sure, but we must not forget that more and more players are being approved. THRM must therefore announce its product and get it approved quickly in order to keep a major part of the market. It takes a certain amount of time for people to adopt a product, which is why it must be introduced more quickly. On the other hand, there are so many unknowns as a result of COVID-19 that the need for testing could extend over years and never disappear. To be at the forefront as THRM is can only make us happy. A mass-distributed, home-based saliva test meets people's demand very well and would cover a large part of the population providing huge revenues and a profit margin on contracts of up to 50%. The sooner we have the product and its characteristics, the sooner we will be able to deduce what will become of THRM's share value.
 
 
<< Previous
Bullboard Posts
Next >>